Category: 3. Business

Story Continues

Peet, a notable player in the Australian property scene, has shown resilience with its debt to equity ratio improving from 57.1% to 53.5% over five years. Despite a high net debt to equity ratio of 45.8%, its interest payments are well covered by EBIT at 10.7 times, reflecting robust financial health. The company reported earnings growth of 60% last year, outpacing the real estate industry average of 40.9%. With sales jumping from A$292 million to A$415 million and net income rising from A$36 million to A$58 million, Peet’s strategic review led by Goldman Sachs aims to leverage these strong market conditions further.

Simply Wall St Value Rating: ★★★★★☆

Overview: Wagners Holding Company Limited is involved in the production and sale of construction and building materials across several countries, including Australia, the United States, New Zealand, the United Kingdom, Papua New Guinea, and Malaysia, with a market capitalization of approximately A$565.22 million.

Operations: Wagners Holding generates revenue primarily from Construction Materials (A$257.69 million), Project Services (A$105.71 million), and Composite Fibre Technology (A$68.45 million). The company also earns a small amount from Earth Friendly Concrete, contributing A$0.16 million to its revenue streams.

Wagners Holding, a nimble player in Australia’s construction materials sector, has seen its earnings surge by 120.9% over the past year, outpacing industry growth. The company recently expanded its concrete and quarry operations to capitalize on infrastructure demand in Southeast Queensland. Despite sales dipping to A$431 million from A$481 million last year, net income climbed to A$22.72 million from A$10.28 million, highlighting improved operational efficiency with high-quality earnings and satisfactory debt management at a 12.6% net debt-to-equity ratio. Wagners’ inclusion in the S&P/ASX Emerging Companies Index underscores its growing market presence amidst strategic expansions and sustainability-focused ventures like Composite Fiber Technologies (CFT).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ASX:DUI ASX:PPC and ASX:WGN.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

At Fortune’s Global Forum in Riyadh, Saudi Arabia, on Sunday, Amini founder and CEO Kate Kallot said her company is building computing power that will enable purpose-built AI solutions for Africa.

The former Nvidia executive also predicted that AI will add $2.9 trillion to Africa’s economy over the next five years as governments begin to view data and computing capacity as critical infrastructure, alongside roads and hospitals. Kallot served as head of emerging areas at Nvidia before departing in 2022 to start Amini.

As infrastructure investments grow, governments are demanding that large language models deployed in Africa actually reflect local realities, given that nearly a billion Africans are still offline while LLMs are trained on internet data, Kallot said.

This new mindset of strategic partnerships has expanded from the governmental level to the private sector, and startups have emerged that will help shape the future of their countries and their economies, she said.

“We’re seeing technology and AI as potentially one of the biggest equalizers that Africa has ever seen,” Kallot added.

But that’s not yet reflected in the global narrative, which doesn’t recognize AI innovation in Africa, she pointed out.

The reality is that the continent is actually a leader in developing AI that’s efficient, responsible, and inclusive—and the rest of the world is about to find out.

“Within the next five to 10 years, we’re going to see African intelligence being exported in other countries across the Global South,” Kallot said.

Changing the global narrative

The negative narrative about Africa is costly, according to Ndidi Okonkwo Nwuneli, CEO of the global advocacy group One Campaign.

That bias has made borrowing costs for African countries more expensive, with negative reporting about the region costing an estimated $4.2 billion. But in fact, certain sectors are seeing returns as high as 10x.

“We’re changing the narrative, and we’re saying Africa is a return on investment, not a risk,” she told Fortune’s Diane Brady. “And this is the time to partner with us with fair financing that delivers results and delivers jobs.”

Flipping the script is also top of mind for Boris Kodjoe, cofounder of the investment and impact platform Full Circle Africa.

The former model and Hollywood actor noted that Africa’s diaspora—the world’s third-largest after China’s and India’s—has been structuring its capital in recent years and is key to the growth story.

Today, Africa’s economy is young, creative, digital, and moving fast, defining itself with culture and technology rather than just its natural resources, Kodjoe explained.

“Africa is the only region where population is getting younger, more connected, and more entrepreneurial all at the same time,” he added. “I think the world is no longer asking ‘why Africa,’ but ‘when can we get in?’ And i think the time is now.” 

Stay informed with free updates

Simply sign up to the Oil & Gas industry myFT Digest — delivered directly to your inbox.

Nigeria’s leading industrialist Aliko Dangote is planning to expand capacity at his group’s petroleum refinery to 1.4mn barrels per day and will sell shares in the business to help finance the expansion.

Dangote told the Financial Times he would sell up to a 10 per cent stake in the refinery “depending on what the Nigerian market can take” and is also seeking $5bn in financing from Afreximbank, the African trade bank.

The expansion, which the multi-billionaire industrialist announced in Lagos on Sunday, would make the refinery in Lagos, Nigeria’s commercial capital, rival Reliance Industries’ refinery at Jamnagar in India as the biggest in the world. Jamnagar says it has an output of 1.4mn barrels a day.

The plant, which has an existing capacity of 650,000 barrels per day, has yet to reach full throttle.

However, the plan reflected his confidence in the Nigerian economy and a response to rising regional demand, Dangote said, adding that it would help further reduce the continent’s dependence on imports.  

“This expansion reflects our confidence in Nigeria’s future, our belief in Africa’s potential, and our commitment to building energy independence for our continent,” he said.

Dangote is the only African on the Forbes list of the 100 wealthiest people in the world, with an estimated net worth of $26bn.

He said the expansion would require 65,000 workers, most of whom would be Nigerian, and expected it to take three years.

The initial phase of the refinery took nearly a decade to construct from start to finish and cost about $20bn, and Dangote said he had learned lessons from the first phase to reduce the completion time of the second.

George Elombi, the new president of Afreximbank, said his institution was in talks with the Dangote group to provide $5bn in loans towards the expansion.

“We have agreed to look for the money so (the Dangote group) can double production, maximise certain production lines and thereby reduce the price of most of its products,” he told the Financial Times.

This was part of a wider strategy the bank has begun in order to encourage industrialisation and increase support across the continent for the processing of raw materials, he said.  

Since it began producing diesel and aviation fuel, and gasoline in 2024, the Dangote group has shaken up the Nigerian oil market, which after years of mismanagement at state-owned refineries had become dependent on costly imports of refined products.

But it faced difficulties at the outset in securing enough oil from Nigeria’s national oil company NNPC, which owns a 7.2 per cent stake in the refinery.

The group sourced crude from around the world with cargoes from Angola, Brazil, Equatorial Guinea, Ghana and the USA to satisfy demand, but has reduced inflows recently in response to rising global prices.

At an Afreximbank event in Cairo on Saturday, Dangote said the refinery construction had been severely disrupted by the Covid-19 pandemic, but previous support from the African trade bank had helped see the project to completion.

“Without Afreximbank the Dangote refinery wouldn’t have been possible,” he said.  

Introduction

The Gulf Cooperation Council (GCC) is fast emerging as a global leader in biotechnology and digital health. This growth is driven by the unique mix of demographic pressures, economic diversification goals, and health security imperatives experienced in these countries. Saudi Arabia and the UAE are leading the sector’s regional expansion: Saudi Arabia’s recent launch of its National Biotechnology Strategy envisions a contribution of US$34.6 billion to non-oil GDP by 2040, while the UAE’s digital health market is forecast to grow by over 23 percent by 2030, pushing the sector to approximately US$2.65 billion in value.

The expansion of such initiatives strengthens GCC countries’ reputations for delivering high-quality healthcare for both locals and expatriates and aligns with wider economic transformation agendas. The biotechnology industry and health tourism sector are lucrative opportunities with estimated values of US$1.5 trillion and US$8.7 billion, respectively.

The biotechnology industry and health tourism sector are lucrative opportunities with estimated values of US$1.5 trillion and US$8.7 billion, respectively.

However, while intensive public and private investment in initiatives such as digital health partnerships, national genome programmes, and AI-driven diagnostics mark major progress, the sector still faces bottlenecks in research infrastructure and data governance. Consolidating these advances through stronger coordination with research institutions and developing comprehensive health data governance frameworks will be key to turning early gains into lasting global leadership. 

Diseases of modernity: rising wealth, sedentary lifestyles and ageing populations

The Gulf states face a health paradox common to high-income societies: economic gains have brought prosperity and longevity, but also a surge in non-communicable diseases. The WHO estimates that around 74 million people in the Eastern Mediterranean live with diabetes, with prevalence rates in the GCC reaching up to 20 percent. At the same time, life expectancy has risen dramatically from 60 years in the late 1970s to around 83 years in 2025 in the UAE, with similar trends observed across the five other GCC states. This puts increasing pressure on both hospitals and home-based care services, given that 80 percent of healthcare needs typically occur post-retirement age.

To meet these needs, states are seeking to implement new technologies within their healthcare offerings. Saudi Arabia’s Digital Health Strategy and Roadmap explicitly includes remote monitoring, virtual clinics, and the integration of telehealth as priorities under Vision 2030 and related health transformation programmes, incorporating technologies that can provide more accessible healthcare to citizens who may have limited mobility. This is also particularly important given Saudi Arabia’s large population and vast geography, as it enables care delivery to more people without extensive travel. In the UAE, ambitions for the health sector outlined in Vision 2021 and the more recent We the UAE 2031 consist of enhancing quality of life and specialised care offerings by continuing to develop an innovative, state-of-the-art healthcare system. As such, the Department of Health’s (DOH) Policy on Digital Health identifies technologies such as “telemedicine, web-based analysis…  wearable devices, and clinic or remote monitoring sensors” as essential for early diagnostics and care management.

Next-generation sequencing and AI are being deployed to analyse population-wide genetic data, identifying variants linked to rare and hereditary disease.

Alongside these efforts, the GCC is deepening its focus on gene mapping and preventative health. The Gulf’s high consanguinity rate among local populations has been a concern for decades, prompting Saudi Arabia to institute a law requiring pre-marital genetic testing in 2002 — the first such law in the region, subsequently adopted across all GCC states. Building on this foundation, targeted testing between couples has now been expanded as governments work to map entire populations. Next-generation sequencing and AI are being deployed to analyse population-wide genetic data, identifying variants linked to rare and hereditary disease. Such projects are essential to the development of “precision medicine”, in which the patient’s specific genetic profile is used to inform and optimise treatment plans rather than relying on generalised clinical guidelines. These programmes also address the Eurocentric bias in earlier datasets, creating population-specific genetic baselines that strengthen diagnostic accuracy.

These initiatives position Gulf countries as leaders in data-driven healthcare, advancing Vision 2030 and We the UAE 2031 goals for economic diversification and improved quality of life. The UAE’s medical tourism market alone was valued at US$334.9 million in 2024, projected to reach US$975 million by 2032. By expanding biotechnology and digital health, both countries aim to extend life expectancy and ease pressure on healthcare systems as populations expand and age.

Building momentum: investment, research and data regulation

Biotechnology and digital health initiatives in the GCC are benefiting from significant levels of government commitment and capital investment. The healthcare-focused private equity company Quadria Capital recently allocated a quarter of its latest US$1 billion fund to the GCC, specifying digital health as a key sub-sector for growth and marking the region as a strategic hub for next-generation healthcare innovation. Saudi Arabia’s flagship Global Health Exhibition saw approximately US$13.3 billion in announced healthcare investment in 2024, and has dedicated a considerable tranche of activities and discussions to the topic of “Digital Health” for the upcoming 2025 edition in late October. In the UAE, the Abu Dhabi Department of Health and the Abu Dhabi Investment Office (ADIO) recently signed an MoU with GSK to establish a medical institute in the emirate, focused on integrating genomics data to advance cancer research. Another strength for the region is the positive reaction that genome projects have received from citizens. Because such projects necessitate a vast amount of data, the voluntary participation of citizens is an essential component. Public support is likely thanks in part to the existence of genetic testing as a pre-marital requirement, in addition to strong public messaging and education campaigns in both the UAE and Saudi Arabia that emphasise the transformative potential of AI’s algorithmic analyses and its central place in the GCC’s future economies.

To ensure long-term competitiveness in medical tourism and biotechnology, GCC countries should expand research capacity alongside treatment infrastructure.

However, challenges related to research capacity and infrastructure, which are uneven across the region, remain. While Abu Dhabi’s Masdar City and Dubai Science Park are key host centres for life sciences firms working in genomics and digital health, most clinical research remains concentrated in only a handful of facilities. The UAE, for example, has only eight on-site research centres across its 168 inpatient facilities. This is also true of Saudi Arabia, where specialist institutions like King Abdullah International Medical Research Center (KAIMRC), King Abdullah University of Science and Technology (KAUST), and King Abdulaziz City for Science and Technology (KACST) are impressive, but relatively few in number compared to global leaders in life sciences innovation, such as the US and Switzerland. To ensure long-term competitiveness in medical tourism and biotechnology, GCC countries should expand research capacity alongside treatment infrastructure. Developing research ecosystems would likely attract more global talent while simultaneously increasing economic gains by driving high-value innovation. In addition, future policy development in the evolving landscape of global data governance must balance security with flexibility — strong enough to guard against high-profile data breaches that have become a persistent risk across the sector, yet open enough to encourage biotech investment. Focusing on research depth and trusted data systems will position the GCC as a secure and innovation-driven healthcare hub.

Conclusion

Over the past decade, the GCC — led by Saudi Arabia and the UAE — has laid the groundwork for a modern, innovation-driven healthcare landscape. Through large-scale investment in the sector, including digital health initiatives and national genome programmes, the region is positioning itself as a global hub for precision medicine and data-driven health innovation. These initiatives address the challenges of population growth, increased life expectancy, and lifestyle-related diseases while supporting broader diversification goals under Vision 2030 and We the UAE 2031. Yet, progress remains uneven, particularly in research infrastructure and regulatory coherence — areas that will determine whether current momentum translates into lasting global influence.

The strong investment trends in the wider sector should be matched by greater allocations toward building specialised research institutions to enable the region to generate original medical advances.

Given that it is the UAE’s ambition to become a global destination for specialised care and Saudi Arabia’s mission to further encourage a competitive environment among healthcare providers, research capacity must become a priority. The strong investment trends in the wider sector should be matched by greater allocations toward building specialised research institutions to enable the region to generate original medical advances. In addition, GCC countries should seek to continuously advance and refine their health data regulations while avoiding overburdening market actors with excessive compliance duties, thereby balancing investor confidence with robust safeguards for privacy and ethical use.

This commentary was originally appeared on ORF Middle East.

The views expressed above belong to the author(s). ORF research and analyses now available on Telegram! Click here to access our curated content — blogs, longforms and interviews.

Story Continues

Result: UNDERVALUED

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Archer Aviation.

Our Discounted Cash Flow (DCF) analysis suggests Archer Aviation is undervalued by 62.0%. Track this in your watchlist or portfolio, or discover more undervalued stocks.

The price-to-book (PB) ratio is a common valuation tool, especially useful for companies that are not yet profitable. For innovative players like Archer Aviation, early gains are typically reinvested for future growth, making traditional measures like price-to-earnings less informative. Instead, PB offers a direct way to see how the market values the company’s assets relative to its book value today.

Growth potential and business risks both affect what counts as a “fair” PB ratio. When investors expect rapid growth or industry-changing breakthroughs, they may accept a higher PB. On the other hand, higher risks or inconsistent financial results usually justify a lower multiple.

Currently, Archer Aviation trades at a PB ratio of 4.33x. This puts it just below the peer average of 4.45x and above the Aerospace & Defense industry average of 3.71x. While these comparisons are helpful, they do not capture the nuances unique to Archer’s profile.

This is where Simply Wall St’s “Fair Ratio” comes in. The Fair Ratio is designed to reflect the PB multiple that best fits Archer’s specific growth outlook, profit margins, risks, and overall market cap. Unlike standard benchmarks, it looks beyond broad industry averages and peer groups, providing a more tailored picture of valuation.

When comparing Archer’s actual PB ratio to the Fair Ratio, the difference is minimal, suggesting the market price is a solid match for its fundamentals right now.

Result: ABOUT RIGHT

PB ratios tell one story, but what if the real opportunity lies elsewhere? Discover companies where insiders are betting big on explosive growth.

Earlier we mentioned that there is an even better way to understand valuation. Let us introduce you to Narratives. A Narrative is your own story or perspective on a company, grounded in your assumptions about its future revenue, earnings, margins, and what you believe is a fair value. Narratives make the numbers come alive by tying your outlook for Archer Aviation directly to a financial forecast and then calculating a fair value based on your beliefs.

On Simply Wall St’s platform, Narratives are easy to create and available for millions of investors to use within the Community page. Narratives help you decide when to buy or sell by comparing your Fair Value to the current Price. They update automatically whenever new information like earnings or major news is released.

This means investors can quickly respond to fresh developments, refine their forecasts, and see how their story stacks up against others. For example, one investor’s Narrative may see Archer’s fair value as high as $36 per share, while another might estimate it at just $11 based on a more cautious outlook.

Do you think there’s more to the story for Archer Aviation? Create your own Narrative to let the Community know!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ACHR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

New data from the Phase 3 BRAVE-AA-PEDS trial highlights baricitinib’s strong performance in adolescents facing severe alopecia areata. Incyte (INCY) and Eli Lilly now plan to pursue global approvals for expanded use based on these results.

See our latest analysis for Incyte.

Incyte’s momentum has really picked up this year thanks to positive trial results and recent pipeline updates, such as its advances in atopic dermatitis and cancer immunotherapies. The stock’s strong 31% share price return since January, along with a 40% total shareholder return over the past year, signals renewed optimism about both its near-term growth and long-term potential.

If Incyte’s clinical breakthroughs have you thinking bigger, this could be a smart time to discover See the full list for free.

With such a run-up in the share price and a fresh wave of optimism, investors have to ask: does Incyte still offer significant upside from here, or has the market already priced in the expected growth?

The most popular narrative among analysts puts Incyte’s fair value at $84.76, which is almost $6.50 below the recent closing price. This signals a view that current market optimism has gone a little too far. Let’s examine one of the biggest factors feeding this analyst consensus.

Recent price target increases highlight optimism about Incyte’s commercial execution, particularly following positive updates on flagship therapies and confidence expressed by new leadership.

Read the complete narrative.

Want the story behind this valuation? Dive in for analysts’ bold projections on future profit margins, share growth, and a crucial earnings target that could make or break the investment case. The real surprise: see how a future multiple drives everything.

Result: Fair Value of $84.76 (OVERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, overreliance on Jakafi and regulatory or competitive pressures could still cast doubt on Incyte’s long-term growth narrative.

Find out about the key risks to this Incyte narrative.

While analyst consensus sees Incyte as expensive at current prices, a fresh look using our SWS DCF model tells a different story. The DCF suggests Incyte could be significantly undervalued, with shares trading at a steep 44% discount to estimated fair value. Are the market and the model seeing something different, or is there an opportunity hiding in plain sight?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Incyte for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

If you have your own perspective or want to dig deeper into the numbers, creating your personalized narrative is quick and straightforward. Do it your way

A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding Incyte.

If you want to stay ahead of the market and uncover the next big opportunity, don’t stand on the sidelines. Let the right tools steer your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include INCY.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Mizuho Financial Group (TSE:8411) shares have been catching investors’ attention following a modest move in recent trading sessions. With returns over the past month slightly negative, but up around 8% in the past 3 months, some are taking a closer look.

See our latest analysis for Mizuho Financial Group.

Mizuho Financial Group’s share price has cooled a bit in the last month, though the backdrop is still positive. Momentum has been building steadily, leading to a 25.74% year-to-date share price return and a striking 63.36% total shareholder return over the past year. This run has caught the market’s eye as investors weigh up growth potential against a changing risk profile.

If you’re looking for fresh ideas beyond the top financial names, this could be the perfect opportunity to discover fast growing stocks with high insider ownership

With shares pulling back just as fundamentals remain largely stable, the key debate is whether Mizuho is trading below its true value or if the market has already factored in all of its future growth potential.

The most widely followed narrative values Mizuho Financial Group higher than its last close, suggesting the stock could be discounted relative to fair value. There appears to be alignment around strong fundamentals driving optimism, setting the stage for a deeper look at what is powering this view.

Strategic acquisitions, partnerships, and cost-cutting initiatives aim to enhance competitive edge, improve efficiency, and expand revenue streams for Mizuho Financial Group. Diversifying revenue sources and enhancing shareholder returns through investments and buybacks could stabilize growth and elevate stock valuation.

Read the complete narrative.

Want to see how ambitious cost-cutting and bold expansion strategies combine to shift the valuation needle? The narrative leans on projections not typically seen for banks in this market environment. Curious what assumptions about earnings growth and margins drive this potential upside? Click through for the full methodology and numbers behind the headline value.

Result: Fair Value of ¥5,231.82 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, rising operational costs and the challenges of integrating new partnerships could put pressure on profitability and could disrupt the positive outlook for Mizuho.

Find out about the key risks to this Mizuho Financial Group narrative.

If you have a different view or want to examine the numbers firsthand, you can build your own perspective in just a few minutes using the same data. Do it your way

A great starting point for your Mizuho Financial Group research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Expand your portfolio’s horizons and never miss your next big opportunity by checking out unique investment ideas that go beyond the familiar names.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include 8411.T.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Please chooseI’m not a medical professional.Allergy and ImmunologyAnatomyAnesthesiologyBiostatisticsCardiac/Thoracic/Vascular SurgeryCardiologyCritical CareDentistryDermatologyDiabetes and EndocrinologyEmergency MedicineEpidemiology and Public HealthFamily MedicineForensic MedicineGastroenterologyGeneral PracticeGeneticsGeriatricsHealth PolicyHematologyHIV/AIDSHospital-based MedicineI’m not a medical professional.Infectious DiseaseIntegrative/Complementary MedicineInternal MedicineInternal Medicine-PediatricsMedical Education and SimulationMedical PhysicsMedical StudentNephrologyNeurological SurgeryNeurologyNuclear MedicineNutritionObstetrics and GynecologyOccupational HealthOncologyOphthalmologyOptometryOral MedicineOrthopaedicsOsteopathic MedicineOtolaryngologyPain ManagementPalliative CarePathologyPediatricsPediatric SurgeryPharmacologyPhysical Medicine and RehabilitationPlastic SurgeryPodiatryPreventive MedicinePsychiatryPsychologyPulmonologyRadiation OncologyRadiologyRheumatologySubstance Use and AddictionSurgeryTherapeuticsTraumaUrologyMiscellaneous

Please chooseI’m not a medical professional.Allergy and ImmunologyAnatomyAnesthesiologyBiostatisticsCardiac/Thoracic/Vascular SurgeryCardiologyCritical CareDentistryDermatologyDiabetes and EndocrinologyEmergency MedicineEpidemiology and Public HealthFamily MedicineForensic MedicineGastroenterologyGeneral PracticeGeneticsGeriatricsHealth PolicyHematologyHIV/AIDSHospital-based MedicineI’m not a medical professional.Infectious DiseaseIntegrative/Complementary MedicineInternal MedicineInternal Medicine-PediatricsMedical Education and SimulationMedical PhysicsMedical StudentNephrologyNeurological SurgeryNeurologyNuclear MedicineNutritionObstetrics and GynecologyOccupational HealthOncologyOphthalmologyOptometryOral MedicineOrthopaedicsOsteopathic MedicineOtolaryngologyPain ManagementPalliative CarePathologyPediatricsPediatric SurgeryPharmacologyPhysical Medicine and RehabilitationPlastic SurgeryPodiatryPreventive MedicinePsychiatryPsychologyPulmonologyRadiation OncologyRadiologyRheumatologySubstance Use and AddictionSurgeryTherapeuticsTraumaUrologyMiscellaneous